

The effects of low-level laser therapy in De Quervain tenosynovitis: evidence from a systematic review and meta-analysis

DOI: <https://doi.org/10.5114/pq/192504>

Hernán Andrés de-la-Barra-Ortiz^{1,2} , Tomás Chavalos De La Maza¹ , María Jesús Gascón-Madrid¹ , Gabriela Hormazábal-Cerda¹ , Alexis Meza-Arellano¹ , Claudio Chamorro-Lange¹ 

¹ Exercise and Rehabilitation Sciences Institute, School of Physical Therapy, Faculty of Rehabilitation Sciences, Universidad Andres Bello, Santiago, Chile

² Physiotherapeutic Resources Research Laboratory, Department of Physical Therapy, Federal University of São Carlos (UFSCar), São Paulo, Brazil

Abstract

Introduction. De Quervain tenosynovitis (QT), a painful and inflammatory wrist condition, presents challenges in its conservative treatment. Although low-level laser therapy (LLLT) is considered an attractive option, the evidence of its effectiveness requires evaluation. This systematic review aimed to assess the analgesic effects of LLLT in QT patients.

Methods. The search used the PubMed, Scopus, Web of Science, Embase, EBSCOhost, Physiotherapy Evidence Database (PEDro), and Google Scholar (last updated on March 10, 2025) databases to identify clinical trials comparing the effects of LLLT to other physical therapy or medical treatments in patients with QT. The primary outcomes evaluated were pain intensity, grip strength, and disability. The Cochrane Risk of Bias Tool 2 (RoB2) assessed study quality, and the meta-analysis used weighted mean difference (WMD) or standardised mean difference (SMD). Evidence-based recommendations for statistically significant outcomes were presented following the GRADE approach.

Results. Eight studies were included, with an overall low risk of bias (RoB) (25%). Deviations from intended interventions and outcome measurement were sources of bias. Post-treatment pain intensity was statistically significant for LLLT (WMD = −0.98 cm; 95% CI: −1.91, −0.04; $p = 0.04$; LLLT group [107], control group [124]). RoB and heterogeneity rated the evidence certainty as very low yet important. Handgrip strength and synovial sheath thickness were not statistically significant between groups ($p > 0.05$).

Conclusions. LLLT reduces pain effectively. Prioritising LLLT or ultrasound (US) over invasive treatments may optimise clinical management and minimise postsurgical complications.

Key words: laser therapy, low-level light therapy, musculoskeletal pain, de Quervain disease, tenosynovitis

Introduction

De Quervain tenosynovitis (QT), first described by Swiss surgeon Fritz de Quervain, is an inflammatory condition characterised by tendon entrapment within the first extensor compartment of the wrist (dorsal first compartment) [1, 2]. QT is characterised by thickening and degeneration of the tendon sheaths surrounding the abductor pollicis longus and extensor pollicis brevis as they traverse the osteofibrous tunnel along the radial styloid in the distal wrist [1, 3].

Risk factors for QT include female gender, age over 40, manual labour, and black race [4]. QT prevalence is 0.5 % in males and 1.3 % in females, peaking between the ages of forty and fifty [4, 5]. Additionally, soft tissue oedema, fluid retention, and ligamentous laxity, commonly affecting women during the last trimester of pregnancy or the postpartum period, contribute to this condition [1, 4].

Medical history and physical examination findings combine to diagnose QT. Patients typically present with pain and oedema localised to the radial styloid region, which is exacerbated by manoeuvres involving ulnar deviation and flexion of the thumb metacarpophalangeal joint [1, 6]. The physical exam commonly includes the Finkelstein test, which reproduces pain when performing these movements and can reveal swelling and tenderness at the radial styloid process [2, 4]. Ultrasonography (USG) aids in diagnosis, particularly in cases requiring corticosteroid injections, by enhancing in-

jection success rates and assisting in preoperative planning for surgical interventions [1, 7].

QT management varies depending on its severity, with conservative options such as nonsteroidal anti-inflammatory drugs and thumb spica splinting providing effective pain management by preventing thumb metacarpophalangeal flexion and ulnar deviation of the wrist [7, 8]. Corticosteroid infiltration into the first extensor compartment prolongs relief in 80% of cases [7], while surgical release of the first compartment, followed by a period of splint immobilisation, is recommended when conservative treatment fails [1, 8].

Physical therapy, a conservative QT treatment option, aims to alleviate pain and improve functionality by encompassing various approaches such as conventional ultrasound (US), manual therapy, therapeutic exercises, and low-level laser therapy (LLLT) [7–9]. LLLT is a non-invasive and painless therapeutic resource that has demonstrated efficacy in managing acute and chronic pain associated with musculoskeletal disorders. Additionally, it has shown effectiveness in controlling inflammation and facilitating soft tissue healing [10–12].

LLLT operates on the principle of light amplification by stimulated emission of radiation (LASER), generating monochromatic light, typically within the red or near-infrared spectrum. LLLT enables the stimulation or inhibition of biological processes through photobiomodulation, which varies depending on the energy delivered to the tissues. The therapy uses

Correspondence address: Hernán Andrés de la Barra Ortiz, Exercise and Rehabilitation Sciences Institute, School of Physical Therapy, Faculty of Rehabilitation Sciences, Universidad Andres Bello, Santiago, 7591538, Chile, e-mail: hdelabarra@unab.cl, handresdelabarra@yahoo.es; <https://orcid.org/0000-0002-3927-1743>

Received: 06.06.2024

Accepted: 21.08.2024

Citation: de-la-Barra-Ortiz HA, De La Maza TC, Gascón-Madrid MJ, Hormazábal-Cerda G, Meza-Arellano A, Chamorro-Lange C. The effects of low-level laser therapy in De Quervain tenosynovitis: evidence from a systematic review and meta-analysis. *Physiother Quart.* 2025;33(3): 1–12; doi: <https://doi.org/10.5114/pq/192504>.

class IIIb lasers with power below 0.5 W [10, 11] to avoid the heating of biological tissues, unlike high-power lasers (class IV) [13]. LLLT reduces inflammation and promotes collagen synthesis and angiogenesis [11]. Additionally, activation of enzymes in the respiratory chain (complex IV) stimulates adenosine triphosphate (ATP), deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) synthesis and cellular metabolism [11, 12, 14]. The physiological mechanisms underlying LLLT-induced analgesia include decreased nociceptive nerve conduction, β -endorphin release, and inflammatory mediator reduction [11–13].

Considering these effects, studies on many musculoskeletal disorders [10, 11, 15], including tendinopathies like QT, have proposed LLLT as a beneficial treatment for reducing pain and inflammation and improving functionality [16–18]. Furthermore, many patients prefer conservative treatment options over surgical release, mainly due to the associated recovery times. However, despite the analgesic benefits of LLLT, the number of clinical trials supporting its effectiveness compared to other treatments seems to be limited. Hence, this systematic review (SR) aimed to gather and assess the existing scientific evidence on the analgesic effects of LLLT in patients diagnosed with QT.

Subjects and methods

Type of study and design

This quantitative SR employed an observational, retrospective, and secondary design. The review adhered to the guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) [19]. Additionally, the SR was registered at the International Prospective Register of Systematic Reviews (PROSPERO) by the National Institute for Health Research with the registration number CRD42024530324 (registration date of March 28th 2024) [20].

Selection criteria

The study adhered to the PICOS approach (patient, intervention, comparison, outcome, and type of studies), focusing on QT patients who received LLLT alone or in addition to other physical therapy treatments that were compared with other physical therapy interventions, medical treatments, or placebos. The primary outcome measure was pain intensity assessment using scales such as the visual analogue scale (VAS) or the numeric pain rating scale (NPRS). Secondary outcomes encompassed alterations in grip strength and disability, evaluated through scales or questionnaires such as the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire. The studies analysed included randomised and non-randomised clinical trials in English or Spanish.

The exclusion criteria comprised case studies, literature reviews, SRs on LLLT unrelated to this study, research involving individuals with QT coexisting with other musculoskeletal disorders or neurological conditions, and studies characterised by incomplete or inaccessible data.

To ascertain eligibility, two researchers (TCH and MJG)) independently evaluated potential studies by scrutinising titles, abstracts, and full texts. A third researcher (HDB) resolved any selection disparities.

Literature review

PubMed, Scopus, Web of Science (WoS), EBSCOhost, Embase, Cochrane, and the Physiotherapy Evidence Database (PEDro) databases. Additionally, the grey literature was explored through the Google Scholar search engine [21].

Keywords derived from the Medical Subject Headings (MeSH) dictionary were used, including “Lasers,” “Laser Therapy,” “Phototherapy,” “Low-Level Light Therapy,” “Laser Class IIIb,” “Musculoskeletal Pain,” “De Quervain Disease,” “Tendinopathy,” and “Tenosynovitis.” The terms were combined using Boolean search syntax to construct the search algorithm: ((“Lasers” OR “Laser Therapy” OR “Phototherapy” OR “Low-Level Light Therapy” OR “Laser Class IIIb”) AND (“Musculoskeletal Pain” OR “De Quervain Disease” OR “Tendinopathy” OR “Tenosynovitis”)).

Data extraction

Three researchers used the Rayyan web tool for the initial screening of article titles and abstracts across multiple databases during the data extraction phase [22], with searches for each database retrieved in nbib, ris, or ciw formats. The three researchers independently evaluated the selected studies and transferred the data to a standardised Microsoft Excel form. Titles and abstracts of potential RCTs or non-RCTs were carefully examined for inclusion. Data extracted from the included reviews encompassed author details, country of origin, publication year, participants, number of groups, selection criteria, treatments, relevant outcomes, assessment instances, conclusions, and funding sources.

Risk of bias and methodological quality

The methodological quality of RCTs was initially assessed using the PEDro scale [23]. The Cochrane Collaboration’s Risk of Bias 2 (RoB2) tool was applied to analyse bias across six domains within the included studies [24]: (a) bias arising from the randomisation process; (b) bias due to deviations from the intended intervention; (c) bias due to missing outcome data; (d) bias in outcome measurement; (e) bias in the selection of the reported result; and (f) overall bias. Studies with a PEDro score of five or less or two or more high-risk bias assessments were categorised as low-quality [25]. The assessment of bias agreement among three researchers (AM, GH, and HDB) was measured using the kappa statistic [26].

Statistical analysis

Statistical analysis was conducted using Review Manager software (RevMan 5.4). Heterogeneity among the studies was evaluated using the chi-squared (χ^2) test and the I^2 statistic. The study weight was calculated as the inverse of its variance, with the combined effect determined as the weighted average of individual effects. Heterogeneity was considered significant when the I^2 coefficient was greater than 50%. [27, 28]. Depending on the level of heterogeneity detected in the meta-analyses, either the Mantel–Haenszel fixed-effect method or the DerSimonian and Laird random-effects method was employed to compute the pooled effect, expressed as weighted mean difference (WMD) or standardised mean difference (SMD), along with 95% confidence intervals (CI), for the reported outcomes of interest. Publication bias was planned to be assessed using funnel plots and Egger’s test [29, 30]

Quality of evidence

The evaluation of evidence quality used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, considering parameters such as study limitations, inconsistency, indirectness, imprecision, and publication bias [27]: (a) study limitations arising from blinding, allocation deficiencies, or overestimation of treatment effects; (b) inconsistency determined by heterogeneity ($P > 50\%$) in main outcomes; (c) indirectness stemming from significant deviations in treated individuals or when compared to less common interventions; (d) imprecision, entailing uncertainty characterised by broad confidence intervals extending across the line of no effect in the meta-analysis, along with the requirement of an optimal sample size for relevance ($n > 400$); (e) when there were fewer than three relevant studies, publication bias could occur.

Evidence levels were assigned, from high to very low, with an initial high-quality rating attributed to each level owing to the exclusive inclusion of RCTs. Factors affecting GRADE domains can lead to a decrease in evidence quality. The significance of the evidence was juxtaposed to ascertain alignment with minimally clinically important differences (MCID). Researchers used the GRADEpro GDT tool to compile a summary table of evidence (www.grade-pro.org) to ensure a thorough synthesis.

Literature search

The search encompassed seven databases, yielding 1,319 articles as of the last update on March 10, 2025: PubMed ($n = 190$), Scopus ($n = 482$), WoS ($n = 251$), EBSCOhost ($n = 126$), Embase ($n = 340$), Cochrane Central ($n = 131$), and PEDro database ($n = 1$). Alternative methods, primarily manual searches on Google Scholar, identified 359 articles. After removing duplicates, 738 articles were selected for further analysis. Screening of titles and abstracts led to the preliminary selection of 15 articles, out of which eight were excluded: three studies on HILT in QT, four on LLLT in other hand con-

ditions, and one SR focusing on physical modalities for hand tenosynovitis. The alternative databases produced 21 documents, including 16 duplicates, with one study on LLLT in other hand conditions, one protocol study, and one webpage about the effects of LLLT. Appendix 1 presents an overview of the studies excluded from the databases, registries, and alternative methods, while Appendix 2 details the search strategy. Ultimately, eight RCTs were included in this review [16–18, 31–35]. Figure 1 illustrates the search strategy using the PRISMA flowchart.

Quality assessment and risk of bias

The methodological quality assessment using the PEDro scale yielded an average score of $5.3 (\pm 1.3)$, with four studies rated as low quality (score < 6) (Table 1). The criteria with the lowest scores were therapist blinding (criterion 6), assessor blinding (criterion 7), and intention-to-treat analysis. In contrast, the highest scores were for adequate follow-up (criterion 8) and group comparisons at the end of treatment (criterion 11). Appendix 2 presents an evaluation of the PEDro scale.

Figure 2 depicts the RoB evaluation with the RoB2 tool, administered by three researchers with a significant concordance ($\kappa = 0.76$) [26]. The criteria with the highest RoB were deviations from intended interventions (50%) and bias in outcome measurement (37.5%). No bias was observed in “missing outcomes” or “bias due to selective reporting.” The overall bias was assessed as 25%.

Characteristics of the included studies

Table 1 summarises the characteristics of the included studies, specifying the author, country, number of participants, study groups, interventions, treatment sessions, outcomes assessed, and findings. The studies were conducted in India [16, 17, 32, 33, 35], Turkey [31, 34], and Egypt [18] between 2002 and 2023. The total number of participants was 320, including 27 men and 246 women with an average age of 35.3 years (± 6.3). Two studies did not specify participant




Figure 1. PRISMA flow chart

Table 1. Study characteristics comparing LLLT for QT

First author (year) country	PEDro score	Participants (n) mean age (± SD)	Inclusion criteria	Exclusion criteria	Groups (n)	Treatments	Sessions	Outcomes	Assessment instances	Results	Sources of funding
Sharma et al. (2002) [16] India	3/10	n = 28 (♂ = 0; ♀ = 28) 33.3 ± 13.2	– diagnosis of QT (uni or bilateral)	– cervical spondylosis with or without radiating pain – hypertension – diabetes – RA	EG (13) CG (15)	EG: LLLT CG: placebo The use of drugs was prohibited during the study.	3 and 10 s	(A) PI (VAS: Finkelstein test) (B) tenderness over radial styloid (Ritchie index) (C) grip and pinch strength (sphygmomanometer) (D) synovial sheath (USG)	T0: baseline T1: post-treatment (2 weeks)	EG: ↓ PI; ↓ tenderness over radial styloid; ↓ synovial sheath* and ↑ grip and pinch strength* CG: ↓ PI; ↓ tenderness over radial styloid; ↓ synovial sheath* and ↑ grip and pinch strength* EG < CG; ↓ PI; ↓ tenderness over radial styloid and ↓ synovial sheath* EG > CG: ↑ grip strength*	University College of Medical Sciences and Guru Teg Bahadur Hospital, Shahdara, Delhi
Amagan et al. (2006) [31] Turkey	5/10	n = 17 (♂ = NS; ♀ = NS) NS	NS	NS	EG (9) CG (8)	EG: LLLT + wrist splint CG: placebo + wrist splint	10 s	(A) PI (VAS) (B) Handgrip strength (sphygmomanometer) (C) global improvement reported by the patient (VSG)	T0: baseline T1: post-treatment (10 days)	EG: ↓ PI*; ↓ VSGI* and ↑ grip strength CG: ↓ PI*; ↓ VSGI* and ↑ grip strength EG < CG; ↓ PI* EG = CG: ↑ VSGI and ↑ grip strength	not reported
Sharma et al. (2015) [17] India	6/10	n = 30 (♂ = 2; ♀ = 28) 36.6 ± 7.2	– diagnosis of QT – without treatment at least (3 months) – Finkelstein test (+)	– cervical spondylosis with or without radiating pain – hypertension – diabetes – upper extremity fractures – RA	EG (15) CG (15)	EG: LLLT CG: US	7 s (2 weeks)	(A) PI (VAS) (B) tenderness over radial styloid (Ritchie index) (C) grip strength (sphygmomanometer) (D) synovial sheath (USG)	T0: baseline T1: post-treatment (2 weeks)	EG: ↓ PI*; ↓ tenderness over radial styloid; ↓ synovial sheath* and ↑ grip strength* CG: ↓ PI*; ↓ tenderness over radial styloid; ↓ synovial sheath* and ↑ grip strength* EG = CG; ↓ PI; ↓ tenderness over radial styloid; ↓ synovial sheath and ↑ grip strength	not funded
Kumar and Mittal (2018) [32] India	6/10	n = 60 (♂ = 6; ♀ = 54) 35.4 ± 6.9	– age 25–35 years – positive Finkelstein test (+)	– cervical spondylosis – hypertension – diabetes – carpal tunnel syndrome – superficial radial neuritis – upper limb fractures – RA	EG (30) CG (30)	EG: LLLT + US CG: LCH injection	7 s (3 weeks)	(A) PI (VAS) (B) tenderness over radial styloid (Ritchie index) (C) grip strength (sphygmomanometer) (D) synovial sheath (USG)	T0: baseline T1: post-treatment (16 weeks)	EG: ↓ PI*; ↓ tenderness over radial styloid; ↓ synovial sheath and ↑ grip strength* CG: ↓ PI*; ↓ tenderness over radial styloid; ↓ synovial sheath and ↑ grip strength* CG < GE; ↓ PI* EG > CG: ↑ grip strength* EG = CG: ↓ synovial sheath	self-funding
Kamalakanan (2020) [33] India	6/10	n = 30 (♂ = NS; ♀ = NS) NS	– diagnosis of QT (uni or bilateral) – Finkelstein test (+)	NS	EG (15) CG (15)	EG: LLLT y K-Tape CG: US + TE	6 s (2 weeks)	(A) PI (VAS) (B) PI affecting QoL (PRWE)	T0: baseline T1: post-treatment (2 weeks)	EG: ↓ PI* and ↑ pain affecting QoL CG: ↓ PI* and ↑ pain affecting QoL EG < CG; ↓ PI* and pain affecting QoL	not reported
Amagan et al. (2021) [34] Turkey	7/10	n = 35 (♂ = 0; ♀ = 35) 42.7 ± 1.3	– diagnosis of QT – pain and tenderness with palpation over the first extensor region – Finkelstein test (+)	– patients who had less pain in 30 days: – history of taking NSAIDs – history of wrist fracture – concomitant disease: diabetes, RA, gout, pseudo gout, pregnant or lactating mothers, and hypertension – corticosteroid injection – surgery – abnormal findings (wrist radiography) – skin conditions making splint wear problematic	EG (18) CG (17)	EG: LLLT + wrist splint CG: wrist splint	15 s (3 weeks)	(A) PI (VAS) (B) handgrip strength (DNM) (C) global improvement reported by the patient (VSGI)	T0: baseline T1: post-treatment (3 weeks)	EG: ↓ PI*; ↑ handgrip strength* and ↑ global improvement reported by the patient* EG: ↓ PI; ↑ handgrip strength and ↑ global improvement reported by the patient EG = CG: ↓ PI; ↑ handgrip strength and ↑ global improvement reported by the patient	not reported
Magda et al. (2021) [18] Egypt	5/10	n = 30 (♂ = 0; ♀ = 30) 28.3 ± 2.8	– age 25–35 years – BMI < 30 kg/m ²	– diabetes – cardiovascular diseases – OA	EG (15) CG (15)	EG: LLLT + TE CG: TE	12 s (4 weeks)	(A) PI (VAS) (B) cortisol levels (blood specimen)	T0: baseline T1: post-treatment (4 weeks)	EG: ↓ PI* and ↓ cortisol levels* CG: ↓ PI* and ↓ cortisol levels* EG < CG: PI* and ↓ cortisol levels*	not reported
Upadhyay et al. (2023) [35] India	4/10	n = 90 (♂ = 19; ♀ = 71) NS	– QT signs and symptoms with USG confirmation – no history of previous treatment – VAS ≥ 5 cm – Finkelstein test (+)	– history of trauma	EG (14) CG 1 (32) CG 2 (25) CG 3 (19)	EG: LLLT CG 1: US CG 2: corticosteroid injection CG 3: surgical release	10 s (4 weeks)	(A) PI (VAS) (B) disability (DASH) (C) therapy satisfaction (self-report)	T0: baseline T1: post-treatment (4 weeks) T2: follow-up (2 weeks after treatment) T3: follow-up (6 weeks after treatment) T4: follow-up (10 weeks after treatment) T5: follow-up (24 weeks after treatment)	EG: ↓ PI*; ↓ disability* and ↑ therapy satisfaction CG 1: ↓ PI*; ↓ disability* and ↑ therapy satisfaction CG 2: ↓ PI*; ↓ disability* and ↑ therapy satisfaction CG 3: ↓ PI*; ↓ disability* and ↑ therapy satisfaction CG 4 < CG 3 < CG 2 < CG 1: ↓ PI* and ↓ disability*	not funded

♂ – men, ♀ – women, BMI – bone mass index, CG – control group, DASH – the disabilities of the arm: shoulder and hand questionnaire, DNM – dynamometry, EG – experimental group, LCH – Langerhans cell histiocytosis, LLLT – low-level laser therapy, OA – osteoarthritis, PI – pain intensity, PRWE – patient-rated wrist evaluation, QoL – quality of life, QT – de Quervain's tenosynovitis, NSAIDs – non-steroidal antiinflammatory drugs, NPRS – numeric pain rating score, NS – not specified, RA – rheumatoid arthritis, T1, T2..., TX – evaluations carried out after treatment, TENS – transcutaneous electrical nerve stimulation, US – therapeutic ultrasound, VAS – visual analog scale, VSGI – verbal scale global improvement; * $p < 0.05$




Figure 2. Risk of bias summary: assessment of bias in each study

gender [31, 35]. A total of 129 subjects received LLLT, either alone [16, 17, 35] or combined with other interventions such as splint immobilisation [31, 34], therapeutic US [32], K-Tape [33], and therapeutic exercise [18]. The controls included 191 participants treated with wrist splints [31, 34] and US [17, 33, 35]. Some controls were treated with corticosteroid injections, decompression surgery [35], and Langerhans Cell Histiocytosis (LCH) injections [32]. Only one study included a placebo control for LLLT [31].

Outcomes

Pain was assessed using tools such as the VAS [16–18, 32, 33–35] and the Ritchie Index for tenderness [16, 17]. Three studies evaluated grip strength using a sphygmomanometer or manual dynamometry [16, 17, 34]. Two studies employed USG to gauge the thickness of the synovial sheath within the initial compartment, measuring both anteroposterior and mediolateral diameters [16, 17]. Only one study evaluated disability using the DASH questionnaire [35]. Other outcomes assessed included patient-reported improvement using the Verbal Scale Global Improvement (VSGI) [31, 34], quality of life using the Patient-Rated Wrist Evaluation (PRWE) [33], and blood cortisol levels [18].

LLLT dosage

Table 2 outlines the LLLT parameters used in the studies. All lasers were infrared As-Ga-Al diodes with wavelengths of 830 nm, except for one study that used 904 nm [33]. The mean treatment power ranged between 30 and 100 mW, with spot applications over the radial styloid process. Only one study reported a combination of punctual and scanning applications [17]. The spot size varied between 1.57, 4.9, and

12.6 cm². Treatment time ranged from 100 to 600 s, with a mean of 284 s (± 200.6). Energy dosage ranged from 3 to 24 J, with a mean of 16.3 J (± 16.5).

Results

Table 3 summarises intragroup results for the outcomes of interest. Both the experimental group (EG) and control group (CG) exhibited statistically significant disparities in pain intensity ($p < 0.05$) [16–18, 31–35], disability [35], and muscle strength [16, 17, 32, 34] at the end of the treatment. Other outcomes, such as synovial sheath thickness of the first compartment [16, 17], blood cortisol levels [18], and quality of life [33], also showed marked changes in both groups. Three studies did not provide sufficient quantitative information for the reported outcomes in terms of central tendency and dispersion measures [16, 31, 32].

Meta-analysis

Pain intensity: The meta-analysis used six studies to scrutinise the analgesic effects of LLLT in contrast to alternative treatments (Figure 3A) [17, 18, 32–35]. The Dersimonian-Laird random effects model assessed the WMD derived from the MD, with differences in favour of LLLT observed (WMD = −0.98; 95% CI: −1.91, −0.04; $p = 0.04$; EG ($n = 107$), CG ($n = 124$) with substantial heterogeneity [27, 28]. Sensitivity analysis by excluding studies with the lowest methodological quality showed a greater analgesic effect (WMD = −1.50 cm; 95% CI: −2.11, −0.88; $p = 0.01$; EG ($n = 93$), CG ($n = 93$), but heterogeneity remained (Figure 3D).

Figure 4 shows the evaluation of publication bias for pain intensity [29, 30]. The distribution for each mean difference (MD) measure extends from the middle of the funnel to the

Table 2. Characteristics and parameters of the lasers used in the included studies

Characteristics/ parameters	Sharma et al. (2002) [16]	Armagan et al. (2006) [31]	Sharma et al. (2015) [17]	Kumar and Mittal (2018) [32]	Kamalakkannan (2020) [33]	Armagan et al. (2021) [34]	Magda et al. (2021) [18]	Upadhyay et al. (2023) [35]
Laser model	endolaser 476 (enraf nonius)	endolaser 476 (enraf nonius)	endolaser 476 (enraf nonius)	endolaser 476 (enraf nonius)	NS	endolaser 476 (enraf nonius)	NS	NS
Wavelength (nm)	830 nm (diode Ga-As-Al)	830 nm (diode Ga-As-Al)	830 nm (diode Ga-As-Al)	830 nm (diode Ga-As-Al)	904 nm (NS)	830 nm (diode Ga-As-Al)	830 nm (diode Ga-As-Al)	NS
Mode (continuous/pulse)	continuous	continuous	continuous	NS	NS	continuous	continuous	NS
Output power (mW)	30–40 mW	100 mW	30–40 mW	30–40 mW	NS	100 mW	30–40 mW	NS
Mean power (mW)	30–40 mW	100 mW	30–40 mW	NS	NS	100 mW	30–40 mW	NS
Frequency (Hz)	/	/	/	NS	NS	/	/	NS
Phase duration (µs)	/	/	/	NS	NS	/	/	NS
Spot size (cm²)	4.9 cm²	1.57 cm²	4.9 cm²	NS	NS	1.57 cm²	12.6 cm²	NS
Treatment protocol	punctual on radial styloid	painful dorsa radial area	punctual and scanning along radial styloid	punctual on radial styloid	punctual on radial styloid	painful dorsa radial area	painful dorsa radial area (10 tender points)	NS
Energy density (J/cm²)	4 J/cm² or 2 J/cm² (according PI with VAS)	NS	3 J/cm² or 2 J/cm² (according PI with VAS)	NS	0,25 y 1,3 J/cm²	NS	20 J/cm²	NS
Total energy (J)	NS	3 J	NS	37 J	NS	3 J	18–24 J	NS
Treatment area (cm²)	4 cm²	NS	3 cm²	NS	NS	NS	NS	NS
Treatment time (s)	NS	300 s	100 s	120 s	NS	300 s	600 s (60 s per point)	NS

Ga-As-Al – gallium aluminium arsenide, NS – not specified, PI – pain intensity, VAS – visual analog scale




Figure 3. Forest plots for pain intensity (visual analogue scale) (3A), strength (3B), and synovial sheath thickness (ultrasonography) at the end of treatment (3C). Sensitivity analysis excludes studies with lower methodological quality to manage heterogeneity (3D)

Table 3. Results and intragroup statistical comparisons for outcome measures before and after treatment

Author	Outcome (instrument)	EG				CG				
		baseline mean ± <i>SD</i>	post-treatment mean ± <i>SD</i>	<i>p</i> -value	efficacy	baseline mean ± <i>SD</i>	post-treatment mean ± <i>SD</i>	<i>p</i> -value	efficacy	
Sharma et al. (2002) [16]	PI (VAS – Finkelstein test)	without quantitative data								
	tenderness over radial styloid (Ritchie index)									
	grip strength (mm Hg)	130.0 ± 35	150.0 ± 45	< 0.01*	yes	125.0 ± 35	110.0 ± 20	< 0.01*	yes	
	pinch strength (mm Hg)	60.0 ± 10	70.0 ± 10			62.0 ± 12	55.0 ± 15			
	synovial sheath – AP (USG, cm)	0.63 ± 0.21	0.52 ± 0.41			0.65 ± 0.1	0.72 ± 0.8			
	synovial sheath – ML (USG, cm)	0.60 ± 0.3	0.49 ± 0.6			0.60 ± 0.2	0.64 ± 0.4			
Armagan et al. (2006) [31]	PI at rest (VAS)	without sufficient quantitative data				without sufficient quantitative data				
	handgrip strength (sphygmomanometer)									
	global improvement reported by the patient (VSGI)									
Sharma et al. (2015) [17]	PI at rest (VAS)	8.8 ± 1.7	3.4 ± 3.5	< 0.01		9.1 ± 1.5	4.2 ± 3.0	< 0.01	yes	
	tenderness over radial styloid (Ritchie index)	without sufficient quantitative data				without sufficient quantitative data				
	grip strength (mm Hg)	112.1 ± 42.8	133.9 ± 49.8	< 0.01*	yes	117.6 ± 61.0	153.6 ± 70.8	< 0.01*	yes	
	synovial sheath – AP (USG, cm)	0.74 ± 0.14	0.9 ± 0.13			0.9 ± 0.13	0.9 ± 0.14			
	synovial sheath – ML (USG, cm)	0.44 ± 0.13	0.4 ± 0.14			0.43 ± 0.01	0.41 ± 0.07			
Kumar and Mittal (2018) [32]	PI (VAS – Finkelstein test)	8.8 ± 1.6	4.2 ± 3.4	< 0.01*		9.1 ± 1.6	4.2 ± 3.4	< 0.01*	yes	
	tenderness over radial styloid (Ritchie index)	without sufficient quantitative data								
	grip strength (sphygmomanometer, mm Hg)	111.2 ± 42.4	136.4 ± 49.6	< 0.01*	yes	113.6 ± 49.6	196.32 ± 69.8	< 0.05*	yes	
	synovial sheath – AP (USG, cm)	without sufficient quantitative data				without sufficient quantitative data				
	synovial sheath – ML (USG, cm)									
Kamalakkannan et al. (2020) [33]	PI at rest (VAS)	7.9 ± 0.7	4.1 ± 0.8	< 0.01*	yes	8.0 ± 0.7	5.7 ± 0.6	< 0.01*	yes	
	PI affecting QoL (PRWE)	8.1 ± 0.8	5.6 ± 0.8			8.1 ± 0.8	7.4 ± 0.3			
Armağan et al. (2021) [34]	PI at rest (VAS)	7.2 ± 1.6	6.0 ± 0.2	< 0.01*	yes	7.2 ± 1.6	7.1 ± 0.2	< 0.01*	yes	
	grip strength (N)	0.4 ± 0.01	0.4 ± 0.01	0.02*		0.4 ± 0.01	0.4 ± 0.01	0.456	no	
	global improvement reported by the patient (VSGI)	3.4 ± 0.17	2.78 ± 0.14	< 0.01*	yes	3.06 ± 0.18	2.9 ± 0.15	0.379	no	
Magda et al. (2021) [18]	PI at rest (VAS)	3.6 ± 0.5	0.3 ± 0.5	< 0.01*	yes	3.7 ± 0.5	2.5 ± 0.9	< 0.01*	yes	
	cortisol levels (blood specimen)	19.6 ± 2.9	6.8 ± 1.2			19.3 ± 2.6	16.1 ± 2.6			
Upadhyay et al. (2023) [35]	PI at rest (VAS): EG vs CG1	6.6 ± 0.8	1.5 ± 1.3	< 0.01*	yes	6.5 ± 0.7	1.1 ± 0.8	< 0.01*	yes	
	PI at rest (VAS): EG vs CG2					6.5 ± 0.8	0.9 ± 0.8			
	PI at rest (VAS): EG vs CG4					6.8 ± 0.6	0.4 ± 0.5			
	disability (DASH – %): EG vs CG1	67.9 ± 7.5	5.7 ± 7.6			65.2 ± 6.7	2.3 ± 4.9			
	disability (DASH – %): EG vs CG2					64.7 ± 9.1	1.8 ± 4.1			
	disability (DASH – %): EG vs CG3					68.9 ± 5.2	0			

EG – experimental group, CG – control group, PI – pain intensity, VAS – visual analog scale, AP – anteroposterior view, ML – medial-lateral view, USG – ultrasonography, VSGI – verbal scale global improvement, QoL – quality of life, PRWE – Patient Rated Wrist Evaluation, DASH – the disabilities of the arm, shoulder, and hand questionnaire; * statistical significance

top, indicating good or fair precision given the homogeneous sample sizes, accompanied by a symmetrical MD distribution, although with values crossing the line of no effect. The Egger’s regression test ruled out publication bias ($p = 0.161$), suggesting the absence of a small study effect [30]. The evidence on the analgesic effects of LLLT was assessed as important, albeit with low certainty (Table 4).

Handgrip strength: The meta-analysis included four studies (Figure 3B) [16, 17, 32, 34]. The DerSimonian and Laird random effect analyses were applied to ascertain the SMD. No statistically significant differences favouring either group were discerned (SMD = -0.07 ; 95% CI: $-0.92, 0.78$; $p = 0.87$; EG ($n = 76$), CG ($n = 77$), and substantial heterogeneity was present [27, 28]. The quality of the evidence was not assessed since there was no difference between the groups to warrant a recommendation grade.

Synovial sheath thickness: Two studies were included in the meta-analysis (Figure 3C) [16, 17]. Due to the absence of heterogeneity, the Mantel–Haenszel fixed-effect method was used. No differences were observed between the groups for the reduction in anteroposterior diameter (WMD = -0.07 mm; 95% CI: $-0.05, 0.12$; $p = 0.47$; EG ($n = 28$), CG ($n = 28$) and mediolateral diameter (WMD = 0.00 mm; 95% CI: $-0.08, 0.08$; $p = 0.94$; EG ($n = 28$), CG ($n = 28$) measured by USG. The quality of the evidence was not assessed since there was no difference between the groups to warrant a recommendation grade [29].

Disability: A meta-analysis was not conducted for disability because it was only reported as a relevant outcome by one study [35].




Figure 4. Evaluation of publication bias for the pain intensity outcome using a funnel plot (left) and Egger’s regression method (right)

Table 4. Summary of findings and quality of evidence (GRADE) for the main outcome

Certainty assessment							No. of patients		Effect	Certainty	Importance ^(e)
no. of studies	study design	risk of bias	inconsistency	indirectness	imprecision	publication bias	LLLT	other physical therapy or medical interventions	absolute		
									(95% CI)		
Pain intensity (assessed with: VAS)											
6	RCT	serious ^(a)	serious ^(b)	not serious ^(c)	serious ^(d)	none	107	124	WMD −0.98 lower (−1.91 to −0.04)	⊕○○○ low	important

LLLT – low-level laser therapy, WMD – weighted mean difference, VAS – visual analog scale
(a) The overall risk of bias was generally low (25%). Sources of bias included outcome measurement (37.5%) and intervention deviations (50%); (b) The heterogeneity determines the inconsistency, depending on the *I*² statistic (≥ 50%); (c) Considering a direct comparison of interventions and outcomes relevant to the study, with applicability to the clinical context, it was found that the indirect evidence held little significance; (d) Imprecision was assessed by examining the width of the confidence interval (CI) for the pooled mean difference, the crossing of the no-effect line in the meta-analysis, and the sample size (*n* < 400); (e) The MD’s relationship to the minimally clinically important difference (MCID) determines the significance

Discussion

LLLT is a non-thermal photobiological modality in the red or near-infrared spectrum used to stimulate tissue repair, reduce pain, and decrease inflammation. These effects have bolstered its use in managing various musculoskeletal conditions, including tendinopathies. With this background, the present review was developed to evaluate the analgesic efficacy of LLLT in QT treatment.

Although the main results show that LLLT can relieve pain, it is no more effective than control interventions at improving grip strength or reducing the thickness of swollen synovial sheaths. Despite the evident analgesic advantages, it is imperative to acknowledge the heterogeneity inherent in the meta-analysis, signifying variations across studies. Consequently, the assessment of the evidence is deemed significant, albeit with a degree of uncertainty.

LLLT and pain reduction

LLLT effectively reduces VAS-determined pain in QT patients when applied alone [16, 17, 35] and in combination with other physical therapy treatments such as splint immobilisation [31, 34], US [32], K-Tape [33], and therapeutic exercise [18]. The results were significantly in favour of LLLT within and between groups. Nevertheless, these values fall below the reported minimal clinically important difference (MCID) of 1.37 cm for VAS [36]. Furthermore, it has been suggested that a change of 2.8 cm (± 2.1) for patients with baseline VAS pain scores of at least 6.7 can represent a clinically significant change in pain severity (MIC) from the patient’s perspective [37]. The meta-analysis did not reflect this MIC, but intragroup comparisons before and after LLLT treatment did.

Although LLLT is thought to have analgesic effects, particularly in nociceptive and neuropathic pain, the specific un-

derlying mechanisms are controversial. The widely accepted hypothesis suggests that the oxidised cytochrome c oxidase (CCO) enzyme, the terminal part of the electron transport chain, absorbs radiation because of its photosensitivity to light [11, 14]. CCO acts as a photoacceptor for red and infrared wavelengths through copper and iron chromophores, leading to increased cellular metabolism and ATP production. Additionally, LLLT promotes nitric oxide release through photodissociation from CCO, increasing the rate of ATP production and promoting vasodilation, thereby modulating reactive oxygen species (ROS) [38, 39]. ROS are implicated in inflammatory, neuropathic, and persistent pain, promoting neuronal excitability in nociceptive pathways and triggering mitochondrial dysfunction and neuroinflammation [38]. Additionally, ROS contribute to the activation of transient receptor potential channels (TRP), rendering transient receptor potential vanilloid 1 (TRPV1) more sensitive and activating transient receptor potential A1 (TRPA1) [40].

LLLT induces analgesia by stimulating endogenous opioid peptide synthesis, such as β-endorphin, while simultaneously reducing the activity of bradykinin and C fibres [41]. Additionally, LLLT initiates morphological alterations in neurons, leading to a reduced mitochondrial membrane potential and a deceleration or inhibition of nerve conduction, thereby attenuating nociceptive transmission [10, 13, 41]. Neurons of the dorsal root ganglion (DRG) specifically exhibit these effects [42]. Furthermore, LLLT mitigates the release of pro-inflammatory neuropeptides, such as substance P and calcitonin gene-related peptide (CGRP), which play pivotal roles in neurogenic inflammation [39, 41].

Evidence suggests that LLLT may increase serotonin (5-HT) production in the central nervous system, favouring the activation of descending pain modulatory pathways [39, 41]. Through the 5-HT1a, 5-HT1b, 5-HT2c, 5-HT3, and 5-HT4 receptors, the 5-HT pathway from the rostral ventromedial

medulla changes how pain signals are sent in the dorsal horn [43]. The diminution of signalling molecules implicated in the inflammatory cascade, including nuclear factor kappa B (NF- κ B), which can hinder prostaglandin E2 (PGE2), tumour necrosis factor- α (TNF- α), cyclooxygenase-2 (COX-2), and interleukin 1 (IL-1), may also explain the analgesic effects of LLLT [39].

Heterogeneity observed for pain intensity

The I^2 index determines heterogeneity, which was evident in the pain intensity meta-analysis. This heterogeneity indicated variability among the studies, which affects the validity of the conclusions drawn from combining the RCT results [27, 28]. These variations may be due to differences in sample size, randomisation, or the measurement of outcomes of interest [27, 28].

Despite attempts to perform a sensitivity analysis by excluding studies with lower methodological quality [35], significant heterogeneity persisted. Additionally, excluding studies can increase publication bias, leading to a small study effect that overestimates the results. Consequently, the authors opted to retain the initial analysis results.

LLLT and synovial sheath thickness

LLLT has been shown to effectively reduce synovial sheath thickness by the end of treatment, though it does not surpass control treatments such as US [17, 35]. This application is grounded in the anti-inflammatory effects of LLLT, supported by various physiological mechanisms. Indeed, wavelengths between 632 and 904 nm induce significant anti-inflammatory effects comparable to nonsteroidal anti-inflammatory drugs (NSAIDs) [44]. These effects include the inhibition and/or attenuation of inflammatory mediators and pain markers, such as TNF- α , IL-1 β , IL-6, COX-2, and PGE2 [44, 45].

In certain scenarios where corticosteroid injections are used to treat QT, the anti-inflammatory efficacy of LLLT may be compromised [35, 46]. Corticosteroid injections are successful in 73.4% of cases with two applications but have a higher failure rate in women with a high body mass index (BMI > 30 kg/m²) [46]. Therefore, LLLT could be an effective alternative to steroid injections in overweight women with QT.

There is evidence that both red and infrared LLLT have a dose-dependent anti-inflammatory effect, with a median average power output of 25 mW [44]. According to the Arndt-Schultz law [47], biostimulation is observed at doses ranging from 0.05 to 10 J/cm², with an optimal range between 0.5 and 4 J/cm², which has been associated with reduced pain and inflammation [44, 48]. A dose of 0.6 J/cm², with an irradiation time of at least 16 s, yields the lowest energy densities for anti-inflammatory effects, while a dose of 3 J/cm² for 300 s yields better effects [44].

LLLT and grip strength

Although LLLT therapy focuses on pain reduction, this review demonstrates an increase in grip strength at the end of treatment, although it was not shown to be superior to control treatments. Pain influences the ability to generate muscle strength due to reflex inhibition and structural changes associated with the clinical condition [49, 50]. Moreover, a reduction in strength of up to 20–30% in a painful limb appears to be typical in chronic pain patients [51].

The assessment of grip strength is essential for understanding hand function. Therefore, the authors recommend maintaining it as a relevant outcome variable for future studies.

LLLT and disability

Despite the close relationship between pain and disability, only one study using the DASH questionnaire considered this variable as a relevant outcome [35]. Pain, particularly in chronic cases, commonly restricts functional capacity, leading to heightened pain perception due to physical inactivity and reduced mobility [52]. However, the relationship between the duration, intensity, extent, and meaning of pain does not always show a linear correlation with disability [52, 53]. The authors recognise the complexity of this construct and highly recommend the inclusion of functional outcomes, such as patient-reported outcome measures (PROMs) [54], in (RCTs) and clinical practice.

Recommendations

The optimal dose of As-Ga-Al LLLT to achieve analgesia remains controversial, and the World Association for Photobiomodulation Therapy (WALT) has not established specific dosage recommendations (<https://waltpbm.org/>). Based on the reviewed literature, a mean output power between 30 and 100 mW and an energy dose per point of 3 to 4 joules are suggested, with a minimum application of three points along the radius styloid.

Considering that conservative treatments have shown similar efficacy to injections and surgery, prioritising LLLT or non-thermal US before resorting to injections or surgery in cases of persistent pain is recommended. Using LLLT or US may prevent surgery-related complications such as damage to the superficial radial nerve or the entrapment of extensor tendons.

Although very few studies included therapeutic exercise in their treatments, it may be beneficial to add thumb extension isometric exercises and stretching alongside LLLT [55, 56].

Limitations

In this SR, the authors adhered to PRISMA guidelines [19], registered the protocol in PROSPERO [20], and conducted a comprehensive search across eight electronic sources [21]. However, two main limitations were identified:

1. The RoB may compromise the internal validity of the study due to deviations in the intended interventions and outcome measurement.
2. Heterogeneity among studies limits the quality and recommendation of the evidence. This variability is attributed to the limited number of RCTs available, which also precluded a sensitivity analysis to control for heterogeneity.

These limitations emphasise the need to conduct new RCTs on LLLT in QT with improved methodological quality.

Conclusions

LLLT emerges as a promising resource for the management of QT-associated pain. Although LLLT has demonstrated effectiveness in reducing pain, its benefits on manual grip strength and inflammation of the synovial sheaths do not appear to surpass treatments such as US, splint immobilisation, or corticosteroid injection. Despite acknowledging the analgesic effects of LLLT, the heterogeneity among studies and the low certainty of evidence underscores the need for future RCTs with better methodological quality. Given the close relationship between pain and functional limitation, future studies should maintain grip strength assessment as a relevant outcome measure and incorporate disability evaluation. Furthermore, the authors recommend prioritising the use of LLLT

or US with strengthening and stretching exercises before resorting to invasive options such as injections or release surgery. These recommendations could enhance clinical management and minimise the risk of postsurgical complications.

Ethical approval

The conducted research is not related to either human or animal use.

Informed consent

Informed consent was obtained from all individuals included in this study.

Disclosure statement

No author has any financial interest or received any financial benefit from this research.

Conflict of interest

The authors state no conflict of interest.

Funding

This research received no external funding.

References

- [1] Fakoya AO, Tarzian M, Sabater EL, Burgos DM, Maldonado Marty GI. De Quervain's disease: a discourse on etiology, diagnosis, and treatment. *Cureus*. 2023;15(4):e38079; doi: 10.7759/cureus.38079.
- [2] Ilyas AM, Ast M, Schaffer AA, Thoder J. De Quervain tenosynovitis of the wrist. *J Am Acad Orthop Surg*. 2007; 15(12):757–64; doi: 10.5435/00124635-200712000-00009.
- [3] Challoumas D, Ramasubbu R, Rooney E, Seymour-Jackson E, Putti A, Millar NL. Management of de Quervain tenosynovitis: a systematic review and network meta-analysis. *JAMA Netw Open*. 2023;6(10):e2337001; doi: 10.1001/jamanetworkopen.2023.37001.
- [4] Stahl S, Vida D, Meisner C, Lotter O, Rothenberger J, Schaller H-E, Stahl AS. Systematic review and meta-analysis on the work-related cause of de Quervain tenosynovitis: a critical appraisal of its recognition as an occupational disease: a critical appraisal of its recognition as an occupational disease. *Plast Reconstr Surg*. 2013; 132(6):1479–91; doi: 10.1097/01.prs.0000434409.32594.1b.
- [5] Wolf JM, Sturdivant RX, Owens BD. Incidence of de Quervain's tenosynovitis in a young, active population. *J Hand Surg Am*. 2009;34(1):112–5; doi: 10.1016/j.jhsa.2008.08.020.
- [6] Larsen CG, Fitzgerald MJ, Nellans KW, Lane LB. Management of de Quervain tenosynovitis: a critical analysis review. *JBJS Rev*. 2021;9(9):e21.00069; doi: 10.2106/jbjs.rvw.21.00069.
- [7] Goel R, Abzug JM. De Quervain's tenosynovitis: a review of the rehabilitative options. *Hand*. 2015;10(1):1–5; doi: 10.1007/s11552-014-9649-3.
- [8] Ferrara PE, Codazza S, Cerulli S, Maccauro G, Ferriero G, Ronconi G. Physical modalities for the conservative treatment of wrist and hand's tenosynovitis: a systematic review. *Semin Arthritis Rheum*. 2020;50(6):1280–90; doi: 10.1016/j.semarthrit.2020.08.006.
- [9] Rabin A, Israeli T, Kozol Z. Physiotherapy management of people diagnosed with de Quervain's disease: a case series. *Physiother Can*. 2015;67(3):263–7; doi: 10.3138/ptc.2014-47.
- [10] Cotler HB, Chow RT, Hamblin MR, Carroll J. The use of low level laser therapy (LLLT) for musculoskeletal pain. *MOJ Orthop Rheumatol*. 2015;2(5):188–94; doi: 10.15406/mojor.2015.02.00068.
- [11] Clijisen R, Brunner A, Barbero M, Clarys P, Taeymans J. Effects of low-level laser therapy on pain in patients with musculoskeletal disorders: a systematic review and meta-analysis. *Eur J Phys Rehabil Med*. 2017;53(4):603–10; doi: 10.23736/S1973-9087.17.04432-X.
- [12] Chow R. EBM in action: is laser treatment effective and safe for musculoskeletal pain? *Med J Aust*. 2002;176(4):194–5; doi: 10.5694/j.1326-5377.2002.tb04366.x.
- [13] de la Barra Ortiz HA, Avila MA, Miranda LG, Lievano RE. Effect of high-intensity laser therapy in patients with non-specific chronic neck pain: study protocol for a randomized controlled trial. *Trials*. 2023;24(1):563; doi: 10.1186/s13063-023-07599-0.
- [14] Reddy GK. Photobiological basis and clinical role of low-intensity lasers in biology and medicine. *J Clin Laser Med Surg*. 2004;22(2):141–50; doi: 10.1089/104454704774076208.
- [15] Chow RT, Johnson MI, Lopes-Martins RAB, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. *Lancet*. 2009;374(9705):1897–908; doi: 10.1016/S0140-6736(09)61522-1.
- [16] Sharma R, Thukral A, Kumar S, Bhargava SK. Effect of low level lasers in de Quervain's tenosynovitis. *Physiotherapy*. 2002;88(12):730–4; doi: 10.1016/s0031-9406(05)60716-x.
- [17] Sharma R, Aggarwal AN, Bhatt S, Kumar S, Bhargava SK. Outcome of low level lasers versus ultrasonic therapy in de Quervain's tenosynovitis. *Indian J Orthop*. 2015;49(5):542–8; doi: 10.4103/0019-5413.164050.
- [18] Elsayy D, Magda M, Mohamed M. Efficacy of low-level laser therapy on DE quervain's tenosynovitis after delivery. *Med J Cairo Univ*. 2021;89(9):1715–9; doi: 10.21608/mjcu.2021.197223.
- [19] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Rev Panam Salud Publica*. 2022;46:e112; doi: 10.26633/RPSP.2022.112.
- [20] Schiavo JH. PROSPERO: an international register of systematic review protocols. *Med Ref Serv Q*. 2019;38(2):171–80; doi: 10.1080/02763869.2019.1588072.
- [21] Paez A. Gray literature: an important resource in systematic reviews. *J Evid Based Med*. 2017;10(3):233–40; doi: 10.1111/jebm.12266.
- [22] Valizadeh A, Moassefi M, Nakhostin-Ansari A, Hosseini Asl SH, Saghab Torbati M, Aghajani R, Ghorbani ZM, Faghani S. Abstract screening using the automated tool Rayyan: results of effectiveness in three diagnostic test accuracy systematic reviews. *BMC Med Res Methodol*. 2022;22(1):160; doi: 10.1186/s12874-022-01631-8.
- [23] Cashin AG, McAuley JH. Clinimetrics: physiotherapy evidence database (PEDro) scale. *J Physiother*. 2020; 66(1):59; doi: 10.1016/j.jphys.2019.08.005.
- [24] Fleming E, Moore TH, Boutron I, Higgins JP, Hróbjartsson A, Nejtgaard CH, Dwan K. Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane. *BMJ Evid Based Med*. 2023;28(4):260–6; doi: 10.1136/bmjebm-2022-112102.

- [25] Gonzalez GZ, Moseley AM, Maher CG, Nascimento DP, Costa L da CM, Costa LO. Methodologic quality and statistical reporting of physical therapy randomized controlled trials relevant to musculoskeletal conditions. *Arch Phys Med Rehabil*. 2018;99(1):129–36; doi: 10.1016/j.apmr.2017.08.485.
- [26] McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med*. 2012;22(3):276–82; doi: 10.11613/bm.2012.031.
- [27] Stogiannis D, Siannis F, Androurakis E. Heterogeneity in meta-analysis: a comprehensive overview. *Int J Biostat*. 2023;20(1):169–99; doi: 10.1515/ijb-2022-0070.
- [28] Ioannidis JPA. Interpretation of tests of heterogeneity and bias in meta-analysis: heterogeneity and bias in meta-analysis. *J Eval Clin Pract*. 2008;14(5):951–7; doi: 10.1111/j.1365-2753.2008.00986.x.
- [29] Austin TM, Richter RR, Sebelski CA. Introduction to the GRADE approach for guideline development: considerations for physical therapist practice. *Phys Ther*. 2014; 94(11):1652–9; doi: 10.2522/ptj.20130627.
- [30] Spinelli LM, Pandis N. Publication bias: graphical and statistical methods. *Am J Orthod Dentofacial Orthop*. 2021;159(2):248–51; doi: 10.1016/j.ajodo.2020.11.005.
- [31] Armagan O, Ekim A, Oner C. 823 treatment of DE Quervain's tenosynovitis with low level laser therapy. *Eur J Pain*. 2006;10(S1):214a–214; doi: 10.1016/s1090-3801(06)60826-4.
- [32] Kumar A, Mittal P. Invasive vs non invasive treatment in stenosing tenosynovitis. *Indian J Physiother Occup Ther*. 2018;12(1):70–5; doi: 10.5958/0973-5674.2018.00013.8.
- [33] Kamalakannan M. Efficacy of Kinesio taping and low-level laser therapy versus conventional therapy for De Quervain's tenosynovitis. *Biomedicine*. 2020;40:89–93; doi: 10.51248/V40I1.112.
- [34] Armağan O, Ortanca B, Özgen M, Berkan F, Öner S. Effect of low-level laser treatment in de Quervain's tenosynovitis patients. *Osman J Med*. 2021;106–116; doi: 10.20515/otd.731806.
- [35] Upadhyay KA, Tank PM, Patel HN, Damor HN, Katara DL. Observational study of management of stenosing tenosynovitis at wrist. *J Orthop Spine*. 2023;11(1):8–13; doi: 10.4103/JOASP.JOASP_4_23.
- [36] Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. *Ann Emerg Med*. 2001; 38(6):633–8; doi: 10.1067/mem.2001.118863.
- [37] Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. *Ann Emerg Med*. 2001;38(6):639–43; doi: 10.1067/mem.2001.118012.
- [38] Huang Y-Y, Nagata K, Tedford CE, McCarthy T, Hamblin MR. Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro. *J Biophotonics*. 2013;6(10):829–38; doi: 10.1002/jbio.201200157.
- [39] Wickenheisser VA, Zywtot EM, Rabjohns EM, Lee HH, Lawrence DS, Tarrant TK. Laser light therapy in inflammatory, musculoskeletal, and autoimmune disease. *Curr Allergy Asthma Rep*. 2019;19(8):37; doi: 10.1007/s11882-019-0869-z.
- [40] Tobore TO. Towards a comprehensive theory of non-cancer acute and chronic pain management: the critical role of reactive oxygen and nitrogen species in pain, and opioid dependence, addiction, hyperalgesia, and tolerance. *Adv Redox Res*. 2021;2:100003; doi: 10.1016/j.arres.2021.100003.
- [41] Fabre HSC, Navarro RL, Oltramari-Navarro PVP, Oliveira RF, Pires-Oliveira DAA, Andraus RAC, Fuirini N, Fernandes KBP 5. Anti-inflammatory and analgesic effects of low-level laser therapy on the postoperative healing process. *J Phys Ther Sci*. 2015;27(6):1645–8; doi: 10.1589/jpts.27.1645.
- [42] Chow RT, David MA, Armati PJ. 830 nm laser irradiation induces varicosity formation, reduces mitochondrial membrane potential and blocks fast axonal flow in small and medium diameter rat dorsal root ganglion neurons: implications for the analgesic effects of 830 nm laser. *J Peripher Nerv Syst*. 2007;12(1):28–39; doi: 10.1111/j.1529-8027.2007.00114.x.
- [43] Heijmans L, Mons MR, Joosten EA. A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation. *Mol Pain*. 2021;17:1744 8069211043965; doi: 10.1177/17448069211043965.
- [44] Bjordal JM, Lopes-Martins RAB, Joensen J, Iversen VV. The anti-inflammatory mechanism of low level laser therapy and its relevance for clinical use in physiotherapy. *Phys Ther Rev*. 2010;15(4):286–93; doi: 10.1179/1743 288x10y.0000000001.
- [45] Okita S, Sasaki R, Kondo Y, Sakamoto J, Honda Y, Okita M. Effects of low-level laser therapy on inflammatory symptoms in an arthritis rat model. *J Phys Ther Sci*. 2023;35(1):55–9; doi: 10.1589/jpts.35.55.
- [46] Oh JK, Messing S, Hyrien O, Hammert WC. Effectiveness of corticosteroid injections for treatment of de Quervain's tenosynovitis. *Hand*. 2017;12(4):357–61; doi: 10.1177/ 1558944716681976.
- [47] Evangelista L, De Meo B, Bernabei G, Belloni G, D'Angelo G, Vanzini M, Calzà L, Gallamini M. Ultra-low-level laser therapy and acupuncture Libralux: what is so special?. *Medicines*. 2019;6(1):40; doi: 10.3390/medicines 6010040.
- [48] Zeng Y-J, Lin Y-H, Wang Y-C, Chang J-H, Wu J-H, Hsu S-F, Tsai S-Y, Lin C-H, Wen Y-R. Laser acupuncture-induced analgesic effect and molecular alterations in an incision pain model: a comparison with electroacupuncture-induced effects. *Lasers Med Sci*. 2018;33(2):295–304; doi: 10.1007/s10103-017-2367-7.
- [49] Graven-Nielsen T, Arendt-Nielsen L. Impact of clinical and experimental pain on muscle strength and activity. *Curr Rheumatol Rep*. 2008;10(6):475–81; doi: 10.1007/ s11926-008-0078-6.
- [50] Cantero-Téllez R, Villafañe JH, Valdes K, García-Orza S, Bishop MD, Medina-Porqueres I. Effects of high-intensity laser therapy on pain sensitivity and motor performance in patients with thumb carpometacarpal joint osteoarthritis: a randomized controlled trial. *Pain Med*. 2020;21(10):2357–65; doi: 10.1093/pm/pnz297.
- [51] Van Wilgen CP, Akkerman L, Wieringa J, Dijkstra PU. Muscle strength in patients with chronic pain. *Clin Rehabil*. 2003;17(8):885–9; doi: 10.1191/0269215503cr6 930a.
- [52] Zale EL, Lange KL, Fields SA, Ditte JW. The relation between pain-related fear and disability: a meta-analysis. *J Pain*. 2013;14(10):1019–30; doi: 10.1016/j.jpain.2013. 05.005.
- [53] Moore A, Tumin D. Overlap of pain-related and general measures of disability among adults with chronic pain. *Pain Pract*. 2024;24(1):62–71; doi: 10.1111/papr.13281.
- [54] Churrua K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, Leahy CJ, Braithwaite J. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. *Health Expect*. 2021;24(4):1015–24; doi: 10.1111/hex.13254.

[55] McBain B, Rio E, Cook J, Sanderson J, Docking S. Iso-metric thumb extension exercise as part of a multimodal intervention for de Quervain’s syndrome: a randomised feasibility trial. *Hand Ther.* 2023;28(2):72–84; doi: 10.1177/17589983231158499.

[56] Rutkowski M, Rutkowski K. Potential effects, diagnosis, and management of de Quervain tenosynovitis in the aesthetics community: a brief review, case example, and illustrative exercises. *J Clin Aesthet Dermatol.* 2023;16 (9 Suppl 2):28–31.

Appendix 1. Summary of excluded articles via databases, registries, and other methods

No.	Source	Reason of exclusion	Author	Year	Reference
1	studies via database and registers	LLLT in other hand conditions	Rahman et al.	2024	Rahman MM, Shakoor MA, Ferdous N, Alam MO, Farhad S, Mehedi ABM, et al. Low-level laser therapy for thumb carpometacarpal joint osteoarthritis: a randomized controlled trial. <i>Cureus.</i> 2024;16(4):e57883; doi: 10.7759/cureus.57883.
2	studies via other methods	clinical trial protocol	Reham et al.	2023	Phonophoresis Versus Low-Level Laser on Dequervain. <i>Clinicaltrials.gov</i> . Available from: https://classic.clinicaltrials.gov/ct2/show/NCT06147869 (accessed 28.05.2024).
3	studies via database and registers	HILT in de Quervain syndrome	Dundar et al.	2023	Dundar Ahi E, Sirzai H. Short-term effectiveness of high-intensity laser therapy in de Quervain tenosynovitis: a prospective, randomized, controlled study. <i>Medeni Med J.</i> 2023;38(1):24–31; doi: 10.4274/MMJ.galenos.2023.67279.
4	studies via database and registers	HILT in de Quervain syndrome	Chongkriengkrai et al.	2023	Chongkriengkrai T, Koonalinthip N, Jongprasitkul H, Priyajarukul A, Surarangsit T, Boonhong J. Effectiveness of high-intensity laser application combined with splinting and therapeutic exercise in subacute de Quervain’s tenosynovitis: a pilot study. <i>Lasers Med Sci.</i> 2023;38(1):229; doi: 10.1007/s10103-023-03892-1.
5	studies via database and registers	LLLT in other hand conditions	Kasim et al.	2022	Kasim AH, Viventius Y. Reduced pain and improved quality of life after laser acupuncture therapy for trigger finger. <i>Med Acupunct.</i> 2022;34(4):261–5; doi: 10.1089/acu.2022.0028.
6	studies via database and registers	HILT in de Quervain syndrome	Chongkriengkrai et al.	2021	Chongkriengkrai T, Boonhong J. The effectiveness of high-intensity laser therapy (HILT) on de quervain’s tenosynovitis: a randomized, double-blinded (patient and assessor), controlled trial. <i>Arch Phys Med Rehabil.</i> 2021;102(10):e63–4; doi: 10.1016/j.apmr.2021.07.659.
7	studies via other methods	LLLT website and its effects	Website	2020	De Quervain’s tenosynovitis treatment in Melbourne. <i>Laser Pain Therapy.</i> 2020. Available from: https://laserpaintherapy.com.au/dequervain (accessed 28.05.2024).
8	studies via database and registers	narrative review	Ferrara et al.	2020	Ferrara PE, Codazza S, Cerulli S, Maccauro G, Ferriero G, Ronconi G. Physical modalities for the conservative treatment of wrist and hand’s tenosynovitis: a systematic review. <i>Semin Arthritis Rheum.</i> 2020;50(6):1280–90; doi: 10.1016/j.semarthrit.2020.08.006.
9	studies via other methods	LLLT in other hand conditions	Spies et al.	2018	Spies CK, Langer M, Hahn P, Müller LP, Unglaub F. The treatment of primary arthritis of the finger and thumb joint. <i>Dtsch Arztebl Int.</i> 2018;115(16):269–75; doi: 10.3238/arztebl.2018.0269
10	studies via other methods	narrative review	Goel et al.	2015	Goel R, Abzug JM. De Quervain’s tenosynovitis: a review of the rehabilitative options. <i>Hand.</i> 2015;10(1):1–5; doi: 10.1007/s11552-014-9649-3.
11	studies via database and registers	LLLT in other hand conditions	Brosseau et al.	2005	Brosseau L, Wells G, Marchand S, Gaboury I, Stokes B, Morin M, et al. Randomized controlled trial on low level laser therapy (LLLT) in the treatment of osteoarthritis (OA) of the hand. <i>Lasers Surg Med.</i> 2005;36(3):210–9; doi: 10.1002/lsm.20137.

HILT – high-intensity laser therapy, LLLT – low-level laser therapy

Appendix 2. Search strategy (last updated March 10, 2025)

Search	KEYWORDS	Databases and registers								Alternative methods
		PubMed	SCOPUS	WoS	EBSCOhost	EMBASE	COCHRANE	PEDro	total	Google Scholar
S1	“Lasers”	98.946	1.695.717	297.125	10.662	45.581	25.742		2.173.773	
S2	“Laser Therapy”	50.919	47.949	16.886	12.106	42.512	7.575		177.947	
S3	“Phototherapy”	20.705	41.560	16.238	6.860	40.305	4.013		129.681	
S4	“Low-Level Light Therapy”	8.329	4.918	697	299	669	1.750		16.662	
S5	“Laser class IIlb”	12	1	1	0	0	1		15	
S6	S1 OR S2 OR S3 OR S4 OR S5	154.889	1.729.917	325.346	26.011	117.614	29.494		2.383.271	
S7	“Musculoskeletal Pain”	12.383	21.213	15.868	5.266	23.743	3.236		81.709	
S8	“De Quervain Disease”	377	565	80	201	104	81		1.408	
S9	“Tendinopathy”	10.592	10.318	8.293	5.331	7.823	1.744		44.101	
S10	“Tenosynovitis”	5.449	8.950	4.331	1.230	9.868	414		30.242	
S11	S7 OR S8 OR S9 OR S10	28.006	39.836	28.216	11.768	40.912	5.322		154.060	
S12	S6 OR S11	190*	482*	251*	126*	340*	131*	1*	1.521	359**

*Search algorithm used for formal databases: (“Lasers” OR “Laser Therapy” OR “Phototherapy” OR “Low-Level Light Therapy” OR “Laser class IIlb”) AND (“Musculoskeletal Pain” OR “De Quervain Disease” OR “Tendinopathy” OR “Tenosynovitis”)

** Search algorithm used for identification of studies via other methods: (“Low-Level Light Therapy” OR “Laser class IIlb”) AND (“De Quervain Disease” OR “Tendinopathy” OR “Tenosynovitis”)